Insider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Buys $143,206.98 in Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. acquired 40,114 shares of the stock in a transaction dated Friday, April 17th. The stock was acquired at an average cost of $3.57 per share, for a total transaction of $143,206.98. Following the purchase, the insider directly owned 12,074,010 shares in the company, valued at approximately $43,104,215.70. The trade was a 0.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 20th, Broadwood Partners, L.P. acquired 40,690 shares of Oncocyte stock. The stock was acquired at an average cost of $3.88 per share, for a total transaction of $157,877.20.
• On Thursday, April 16th, Broadwood Partners, L.P. acquired 102,057 shares of Oncocyte stock. The stock was acquired at an average cost of $3.45 per share, for a total transaction of $352,096.65.
• On Tuesday, February 10th, Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock. The stock was acquired at an average cost of $5.75 per share, for a total transaction of $2,999,999.25.

Oncocyte Price Performance

Shares of IMDX opened at $3.75 on Thursday. The stock has a 50 day simple moving average of $4.45. The firm has a market cap of $120.64 million, a PE ratio of -2.31 and a beta of 1.52. Oncocyte Corp has a 12-month low of $2.33 and a 12-month high of $8.51.

Oncocyte (NASDAQ:IMDX) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.27) earnings per share (EPS) for the quarter. The firm had revenue of $1.14 million for the quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IMDX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a research report on Friday, March 27th. Lake Street Capital lifted their target price on shares of Oncocyte from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen downgraded shares of Oncocyte from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oncocyte presently has an average rating of “Hold” and a consensus price target of $12.00.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.